Clinical evaluation of an enamel matrix protein derivative combined with a bioactive glass for the treatment of intrabony periodontal defects in humans.
BACKGROUND
The purpose of the present study was to compare the treatment of deep intrabony defects with a combination of an enamel matrix protein derivative (EMD) and a bioactive glass (BG) to BG alone.


METHODS
Twenty-eight patients with chronic periodontitis, each of whom displayed 1 intrabony defect, were randomly treated with a combination of EMD and BG or with BG alone. Soft tissue measurements were made at baseline and at 1 year following therapy.


RESULTS
No differences in any of the investigated parameters were observed at baseline between the 2 groups. Healing was uneventful in all patients. At 1 year after therapy, the sites treated with EMD and BG showed a reduction in mean probing depth (PD) from 8.07 +/- 1.14 mm to 3.92 +/- 0.73 mm and a change in mean clinical attachment level (CAL) from 9.64 +/- 1.59 mm to 6.42 +/- 1.08 mm (P < 0.0001). In the group treated with BG, the mean PD was reduced from 8.07 +/- 1.32 mm to 3.85 +/- 0.66 mm and the mean CAL changed from 9.78 +/- 1.71 mm to 6.71 +/- 1.89 mm (P < 0.0001). No statistically significant differences in any of the investigated parameters were observed between the test and control group.


CONCLUSIONS
Within the limits of the present study, it can be concluded that both therapies led to significant improvements of the investigated clinical parameters, and the combination of enamel matrix derivative and bioactive glass does not seem to additionally improve the clinical outcome of the therapy.
Sculean
Anton
A
Department of Periodontology and Conservative Dentistry, University of Saarland, Homburg, Germany.
Barbé
Giovanni
G
Chiantella
Giovanni C
GC
Arweiler
Nicole B
NB
Berakdar
Mohammad
M
Brecx
Michel
M
D000134:Acid Etching, Dental; D016301:Alveolar Bone Loss / Q000601:surgery*; D000704:Analysis of Variance; D001672:Biocompatible Materials / Q000627:therapeutic use*; D018786:Bone Substitutes / Q000627:therapeutic use*; D002516:Ceramics / Q000627:therapeutic use*; D002908:Chronic Disease; D003646:Debridement; D003746:Dental Enamel Proteins / Q000627:therapeutic use*; D003774:Dental Plaque Index; D005260:Female; D005500:Follow-Up Studies; D005889:Gingival Recession / Q000601:surgery; D006801:Humans; D008297:Male; D017622:Periodontal Attachment Loss / Q000601:surgery; D010512:Periodontal Index; D010514:Periodontal Pocket / Q000601:surgery; D010518:Periodontitis / Q000601:surgery; D013223:Statistics as Topic; D014092:Tooth Root / Q000187:drug effects; D016896:Treatment Outcome; D014945:Wound Healing
D001672:Biocompatible Materials; C022107:Bioglass; D018786:Bone Substitutes; D003746:Dental Enamel Proteins; C109069:enamel matrix proteins